Arkema S.A. ARKAY has officially opened the expansion of its Shanghai R&D Center in China, strengthening its capabilities to foster innovation, enable synergies within teams and increase engagement with customers in Asia. The investment aligns with the company's global research and development strategy.
The expansion increases laboratory space by around 20% and introduces new collaborative facilities, including an interactive showroom to showcase Specialty Materials solutions. The upgraded center will bring together Arkema’s expertise in the materials business and interaction with the local R&D ecosystem to jointly develop with customers and accelerate innovation in high-performance and sustainable materials.
Established in 2011 as Bostik's Asia Technology Center, the Shanghai facility has developed expertise in materials synthesis, formulation development and application validation. Its innovations are used in high-speed rail, food packaging and sustainable consumer goods. The expansion also aligns with Arkema's One Arkema strategy by strengthening the innovation ecosystem, including start-ups and emerging technology companies.
These investments are expected to reinforce Arkema's interaction with customers and support the development of solutions for high-growth markets, including new energy, electronics, mobility and sustainability. With Specialty Materials accounting for approximately 85% of its 2025 sales, the company's continued R&D investments support its strategic focus on becoming a world leader in Specialty Materials.
ARKAY shares have gained 4.2% in the past year compared with the industry’s 2.5% growth.
Image Source: Zacks Investment Research
ARKAY’s Zacks Rank & Key Picks
ARKAYcurrently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Reliance, Inc. RS, Cabot Corporation CBT and Avient Corporation AVNT.
RS currently sports a Zacks Rank #1 (Strong Buy), while CBT and AVNT carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here
The Zacks Consensus Estimate for RS’ 2026 earnings is pegged at $23.70 per share, indicating a 66.2% year-over-year surge. RSshares have gained 49.7% over the past year.
The Zacks Consensus Estimate for CBT’s current fiscal-year earnings is pinned at $6.35 per share. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters, with an average surprise of 4.56%.CBTshares have gained 8.4% over the past year.
The Zacks Consensus Estimate for AVNT’s fiscal 2026 earnings is pegged at $3.2 per share, indicating a year-over-year rise of 13.48%. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arkema SA (ARKAY): Free Stock Analysis Report
Reliance, Inc. (RS): Free Stock Analysis Report
Cabot Corporation (CBT): Free Stock Analysis Report
Avient Corporation (AVNT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).